Effect of dapagliflozin on heart and blood vessel health in heart failure patients
Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling
This study is testing if adding the medication dapagliflozin to the usual heart failure treatments can improve heart function and blood vessel health in people with heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poznan University of Medical Sciences Academic / other |
| Locations | 1 site (Poznan, Wielkopolska) |
| Trial ID | NCT06679179 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate how dapagliflozin, a medication taken once daily, influences heart function and blood vessel remodeling in patients with heart failure classified as NYHA class II-III. It will assess changes in hemodynamic parameters and explore the potential benefits of this treatment on overall heart health and quality of life. The study builds on existing literature that suggests dapagliflozin may improve heart function and reduce complications associated with heart failure. Participants will already be on standard heart failure medications and will add dapagliflozin to their treatment regimen.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with NYHA class II or III heart failure who are already receiving standard heart failure treatments.
Not a fit: Patients with heart failure who are not on the required background medications or those with contraindications to dapagliflozin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved heart function and quality of life for patients with heart failure.
How similar studies have performed: Previous studies have shown positive outcomes with similar medications in improving heart failure management, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed heart failure NYHA class II and III * consent to participate in the study * patients should already be receiving treatment with an ACE inhibitor or sacubitril/valsartan or sartans, a beta-blocker, and an MRA, and should start on SGLT2i as part of therapy enhancement Exclusion Criteria: -
Where this trial is running
Poznan, Wielkopolska
- University Clinical Hospital in Poznań, 49 Przybyszewskiego Street, 60-355 Poznań — Poznan, Wielkopolska, Poland (Recruiting)
Study contacts
- Principal investigator: Arkadiusz Niklas, PhD — University Clinical Hospital in Poznań, 49 Przybyszewskiego Street, 60-355 Poznań
- Study coordinator: Arkadiusz Niklas, MD PhD
- Email: aniklas@ump.edu.pl
- Phone: 0048 61 854 90 90
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.